ORION CORPORATION STOCK EXCHANGE RELEASE 10 APRIL 2012 at 09.45 AM EEST
Orion will publish its Interim Report January-March 2012 on Tuesday, 24 April 2012 approximatelyat 12:00 Finnish time (EET). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en (http://www.orion.fi/en)promptly after the publishing.
News conference for analysts and mediaon Tuesday 24 April 2012 at 13:30 EEST
A news conference for analysts and mediawill be held on Tuesday 24 April 2012 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review.
Live webcast and conference call
The event can be followed live as a webcast accessible at www.orion.fi/en (http://www.orion.fi/en). Questions can be asked also through conference call lines after the result presentation.
The conference call ID is 914,103 and the phone numbers to participate the conference are:
when calling from the United States +1 334 323 6203
when calling from other countries +44 (0)20 7162 0125
News conference recordings
A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.
Silent period
The silent period preceding the publication is ongoing and continues until the disclosure.
Orion Corporation
| Timo Lappalainen President and CEO | Jari Karlson CFO |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi (http://www.orion.fi)
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
